Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force
Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP
Record ID 32015001088
English
Authors' objectives:
To systematically review evidence for the effectiveness of aspirin to prevent myocardial infarction (MI)/coronary events, stroke, cardiovascular death, and all-cause mortality in those without a history of cardiovascular disease (CVD). To review evidence for harms associated with aspirin use.
Authors' recommendations:
In primary prevention populations, aspirin modestly reduces nonfatal MI/coronary
events and major CVD events, but also increases major GI bleeding risk. More precise realworld
estimates for bleeding events, including major GI bleeding events and hemorrhagic stroke,
are necessary to calculate the net benefit. At some absolute risk for 10-year CVD events, this
absolute CVD benefit could potentially outweigh the bleeding risks. Models to identify these
populations are needed.
Details
Project Status:
Completed
URL for project:
http://www.ncbi.nlm.nih.gov/books/NBK321623/
Year Published:
2015
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Aspirin
- Primary Prevention
- Cardiovascular System
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.